Cayman Brd2 Bromodomain 2 (Human, Recombinant)

Bromodomain-containing 2 (BRD2) is a transcriptional regulator that is a member of the bromodomain and extra-terminal (BET) family.¹ It is ubiquitously expressed and localizes to the nucleus. BRD2 is composed of two N-terminal bromodomains (BD1 and BD2) that bind acetylated lysine on histones, serving to couple histone acetylation marks to the transcriptional regulation of target promoters, and an extra-terminal domain that mediates chromatin interactions.^1,2 BRD2 associates with transcription effector and regulator proteins, including RNA polymerase II, histone acetylases and deacetylases, and transcriptional co-activators and co-repressors to form a transcription complex that regulates the expression of genes involved in inflammation and cell proliferation.^1,3 BRD2 also binds to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) envelope (E) protein, a transmembrane protein involved in CoV virion assembly and pathogenesis of the related virus, SARS-CoV.^4,5,6 The BD2 bromodomain of BRD2 contains four α-helices that form the binding site for the acetylated histone H4 tail.⁷ Point mutations of valine 329 (V329A) or asparagine (N382A) in the BD2 bromodomain eliminate BRD2 binding to acetylated histone H4 lysine 12 (H4K12Ac), and a point mutation of tyrosine 427 (Y427F) abolishes the association between BRD2 and STAT3.^8,9 Cayman’s BRD2 bromodomain 2 (human, recombinant) protein can be used for ELISA, Western blot (WB), and binding assay applications.

WARNING This product is not for human or veterinary use.